Arthur A. Levin - Aug 12, 2022 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Signature
/s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
Stock symbol
RNA
Transactions as of
Aug 12, 2022
Transactions value $
-$1,698,104
Form type
4
Date filed
8/31/2022, 08:08 PM
Previous filing
Jun 8, 2022
Next filing
Jan 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNA Common Stock Options Exercise $7.42K +14K +1052.86% $0.53* 15.3K Aug 12, 2022 Direct F1
transaction RNA Common Stock Sale -$308K -14K -91.33% $22.00 1.33K Aug 12, 2022 Direct F1
transaction RNA Common Stock Options Exercise $14.7K +27.7K +2085.71% $0.53* 29.1K Aug 15, 2022 Direct F1
transaction RNA Common Stock Options Exercise $43.1K +34.8K +119.57% $1.24* 63.8K Aug 15, 2022 Direct F1
transaction RNA Common Stock Sale -$1.38M -62.5K -97.92% $22.12 1.33K Aug 15, 2022 Direct F1, F2
transaction RNA Common Stock Options Exercise $4.34K +3.5K +263.08% $1.24* 4.83K Aug 16, 2022 Direct F1
transaction RNA Common Stock Sale -$77.3K -3.5K -72.46% $22.08 1.33K Aug 16, 2022 Direct F1, F3
holding RNA Common Stock 274K Aug 12, 2022 By family trust F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -14K -33.55% $0.00 27.7K Aug 12, 2022 Common Stock 14K $0.53 Direct F1, F5
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -27.7K -100% $0.00* 0 Aug 15, 2022 Common Stock 27.7K $0.53 Direct F1, F5
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -34.8K -20.85% $0.00 132K Aug 15, 2022 Common Stock 34.8K $1.24 Direct F1, F6, F7
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -3.5K -2.65% $0.00 128K Aug 16, 2022 Common Stock 3.5K $1.24 Direct F1, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.47.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.30.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 On March 18, 2021, the Reporting Person filed a Form 4 reporting the total number of shares indirectly owned through a family trust. These indirect holdings were inadvertently omitted from the Reporting Person's subsequent reports on Form 4 filed on June 16, 2021, June 22, 2021, June 28, 2021 and November 22, 2021.
F5 This option is exercisable as to vested and unvested shares. The option was granted on August 29, 2017 and 1/48th of the shares subject to the option vest monthly.
F6 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter.
F7 On June 11 2020, the Reporting Person filed a Form 3 which inadvertently overreported the number of options under this option grant due to a typographical error. The aggregate number of options beneficially owned has been updated in this Form 4 to reflect the total number of options held by the Reporting Person following the transactions reported on this Form 4 and the Reporting Person's previously filed reports.